Spectroscopic Assessment of Intramyocardial Oxygen Saturation During Open-Heart Surgery — ECS  

Coronary Artery Disease Clinical Trial

Official title: Spectroscopic Assessment of Intramyocardial Oxygen Saturation During Open-Heart Surgery

Status Recruiting

Clinical Trial Summary

The goal of this observational study is to test in the safety and performance of intraoperative myocardial spectroscopic measurement in open-heart surgery patients

The main questions it aims to answer are:

• The Devices can record myocardial spectrometric data for analysis, and

• How these measures correlate with the occurring events, procedures, and clinical parameters during the operation.

• Number of participants with device-related adverse events as assessed by CTCAE v4.0

Clinical Trial Description

The study design is based on measuring the depth of ischemia during the operation, which is compared to the intraoperative and postoperative morbidity of the patient, especially to the dysfunction of the heart. A qualified and experienced Monitor is assigned for the study to oversee and document the progress of the trial. The Monitor ensures the trial performance in accordance with the Protocol and Good Clinical Practice (GCP). The trial team conforms to ISO 13485 quality standards and ISO 14155 GCP. Processes included in the monitoring activities are documented in the quality management system. Below are described the summaries of all these activities. Source data will be collected and transferred into the electronic CRFs by site staff, and the collected data quality and the conformity to the Good Clinical Practice will be assessed by monitoring. Based on a risk assessment performed, a Data Monitoring Committee shall not be established. Clinical Research Associate (CRA) is responsible for checking the accuracy and completeness of Case Report Form (CRF) entries, source documents, and other investigation-related records against each other. Other responsibilities of CRA, including detailed Source Data Verification (SDV), are documented by the clinical project manager (CPM) or head of clinical research (HCR)(both are sponsor's representatives). SDVs will be performed and documented during monitoring visits. Monitoring planning, reporting, and visits are pre-defined and documented with pre-made templates per the sponsor's quality management system. Monitoring visits will be performed to cover data from all study participants, and according to QMS and the Standard Operation Procedures. The monitoring shall ensure that all source documentation is precise and document control is exercised in all relevant documentation. The monitoring ensures, that the Adverse events are always reported and appropriate authorities or stakeholders are informed. ;

Related Conditions & MeSH terms

• Coronary Artery Disease
• Heart Valve Diseases

• NCT number: NCT06084091
• Study type: Observational
• Source: Spectrocor
• Contact: Peter Raivio, PhD
• Phone: +358 50 4272283
• Email: peter.raivio@hus.fi
• Status: Recruiting
• Start date: October 6, 2023
• Completion date: November 30, 2025